Drug treatment of chronic-intermittent abdominal cramping and pain: A multi-national survey on usage and attitudes

S. Mueller-Lissner, E. M.M. Quigley, I. Helfrich, E. Schaefer

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Aliment Pharmacol Ther 2010; 32: 472-477 SummaryBackground Data on drug treatment of abdominal cramping and pain are sparse. Aim To compare treatment of abdominal cramping and pain across countries worldwide. Methods A multi-national survey was conducted in the USA, Mexico, Brazil, Argentina, Germany, Belgium, Italy and the UK. In each country, approximately 210 people were interviewed on various aspects of drug treatment of their complaints. Results In total, 1717 participants were interviewed. Respondents from the Americas used more medication (approximately 90%) than those from Europe (approximately 70%). Over-the-counter remedies were much more used than prescription drugs (except for Mexico). Medication was mainly taken on demand to relieve a pain episode. In the Latin American countries, antispasmodics were most popular (up to 73%), in Germany antacids, and in the UK antacids and analgesics. Regarding expectations of treatment, 'fast onset of action' ranked the highest, followed by 'highly effective' and 'well tolerated'. Conclusions A majority of people afflicted by abdominal cramping and pain use medication and take them on demand. Consequently, rapid onset of action is mentioned as most important. Antispasmodics are the class most frequently used with considerable variation from country to country.

Original languageEnglish (US)
Pages (from-to)472-477
Number of pages6
JournalAlimentary Pharmacology and Therapeutics
Volume32
Issue number3
DOIs
StatePublished - Aug 2010

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Drug treatment of chronic-intermittent abdominal cramping and pain: A multi-national survey on usage and attitudes'. Together they form a unique fingerprint.

Cite this